Cochrane · systematic review · CD010956
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
Wang, X, Ma, Y, Hui, X, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 10 · 83.3%High 2 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT
Population: participants with diagnosed DVT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent VTE (7 months) Oral DTIs vs conventional anticoagulation | OR 1.17 [0.83, 1.65] | 3 studies · 5994 participants | Moderate Downgraded: imprecision, publication bias |
Recurrent DVT (7 months) Oral DTIs vs conventional anticoagulation | OR 1.11 [0.74, 1.66] | 3 studies · 5994 participants | Moderate Downgraded: imprecision, publication bias |
Fatal PE (7 months) Oral DTIs vs conventional anticoagulation | OR 1.32 [0.29, 6.02] | 3 studies · 5994 participants | Moderate Downgraded: imprecision, publication bias |
Non‐fatal PE (7 months) Oral DTIs vs conventional anticoagulation | OR 1.29 [0.64, 2.59] | 3 studies · 5994 participants | Moderate Downgraded: imprecision, publication bias |
All‐cause mortality (7 months) Oral DTIs vs conventional anticoagulation | OR 0.66 [0.41, 1.08] | 1 study · 2489 participants | Moderate Downgraded: imprecision, publication bias |
Major bleeding (7 months) Oral DTIs vs conventional anticoagulation | OR 0.58 [0.38, 0.89] | 3 studies · 5994 participants | High |
Oral factor Xa inhibitors compared to conventional anticoagulation for participants with diagnosed DVT
Population: participants with diagnosed DVT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent VTE (3 to 12 months) Oral factor Xa inhibitors vs conventional anticoagulation | OR 0.85 [0.71, 1.01] | 13 studies · 17505 participants | Moderate Downgraded: imprecision, publication bias |
Recurrent DVT (3 to 12 months) Oral factor Xa inhibitors vs conventional anticoagulation | OR 0.7 [0.49, 1.01] | 9 studies · 16439 participants | Moderate Downgraded: imprecision, publication bias |
Fatal PE (3 to 12 months) Oral factor Xa inhibitors vs conventional anticoagulation | OR 1.18 [0.69, 2.02] | 6 studies · 15082 participants | Moderate Downgraded: imprecision, publication bias |
Non‐fatal PE (3 to 12 months) Oral factor Xa inhibitors vs conventional anticoagulation | OR 0.93 [0.68, 1.27] | 7 studies · 15166 participants | Moderate Downgraded: imprecision, publication bias |
All‐cause mortality (3 to 6 months) Oral factor Xa inhibitors vs conventional anticoagulation | OR 0.87 [0.67, 1.14] | 9 studies · 10770 participants | Moderate Downgraded: imprecision, publication bias |
Major bleeding (3 to 12 months) Oral factor Xa inhibitors vs conventional anticoagulation | OR 0.63 [0.45, 0.89] | 17 studies · 18066 participants | High |